Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment

20260 citationsJournal Article

Authors

Good health and well-being

Published in: International Journal of Clinical Oncology

Volume 31, Issue 3, pp. 467-475

Field-Weighted Citation Impact: 0.00